Application of 3D MR Neurogram for Intraparotid Facial Nerves Evaluation

Last updated: February 10, 2025
Sponsor: Chinese University of Hong Kong
Overall Status: Active - Recruiting

Phase

N/A

Condition

Neoplasms

Treatment

Magnetic Resonance Imaging on 3T scanner (Magnetom Prisma, SIemens) with dedicated neurogram sequences (Constructive interference in steady state - CISS; Dual Echo Steady State - DESS)

Clinical Study ID

NCT05296109
CREC 2021.639
  • Ages > 18
  • All Genders

Study Summary

Parotid neoplasm consists of a wide range of benign and malignant lesions, and parotidectomy has been the mainstay for management of these neoplasms. Within the parotid gland there are branches of the intra-parotid facial nerves, which are tiny in calibre and are prone to injury to injury during operation. It has been reported in recent retrospective view that the incidence of temporary and permanent facial nerve injury were 9.2% and 5.2% respectively, the risk of which increased with old age, malignant tumour and revision surgery. Traditional the incidental of facial nerve injury is reduced by intra-operative facial nerve monitoring and surgical magnification, while imaging has limited role in aiding this purpose. However with advancement in MRI technique high resolution three-dimensional sequences (i.e. neurogram sequences) are available for better visualization of branches of facial nerves. The investigators would therefore aim to demonstrate additional efficacy of these techniques and also to compare with conventional 3D post-contrast anatomical imaging studies in the localization and visualization of the facial nerve branches in patients with tumour. With better pre-operative imaging, the investigators hope to reduce the chance of facial nerve injury in these patients.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Consecutive patients with parotid tumour diagnosed on other imaging modalities (suchas ultrasonography or computed tomography), with or without cytological diagnosisfrom fine needle aspiration, will be recruited from the ear, nose and throatspecialty clinic.

Exclusion

Exclusion Criteria:

  • Patients who are contraindicated to magnetic resonance imaging (such as due tounderlying MRI incompatible metallic implants)

  • Patient who are contraindicated to MRI contrast agents (such as advanced renalfailure or previous severe allergic reaction)

  • Patients who cannot cooperate for MRI scanning.

  • Patients show are unable to provide informed consent.

Study Design

Total Participants: 50
Treatment Group(s): 1
Primary Treatment: Magnetic Resonance Imaging on 3T scanner (Magnetom Prisma, SIemens) with dedicated neurogram sequences (Constructive interference in steady state - CISS; Dual Echo Steady State - DESS)
Phase:
Study Start date:
February 01, 2022
Estimated Completion Date:
June 30, 2026

Connect with a study center

  • Gerald Choa MRI Center

    Hong Kong,
    Hong Kong

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.